Designation Based on Pre-Clinical Data and Initial Clinical Data from the Company's MAvERIC-Pilot Phase II StudyThis is a Designated News…
LONDON, UK / ACCESSWIRE / February 15, 2024 / Poolbeg Pharma (AIM:POLB, OTCQB:POLBF, "Poolbeg" or the "Company"), a biopharmaceutical company…
Edison Histotripsy System Selected for Competitive Accelerated Market Access ProgramMINNEAPOLIS--(BUSINESS WIRE)--#HistoSonics--HistoSonics®, (www.histosonics.com), the manufacturer of the Edison® System and novel…
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness,…
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness,…
LAS VEGAS, NV / ACCESSWIRE / February 14, 2024 / Skinvisible, Inc. ("Skinvisible") (OTCQB:SKVI) is excited to share a promising…
KNOXVILLE, TN, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that…
BOSTON, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Carrick Therapeutics, an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapies, today…
Dr. Yelena Janjigian, Chief of GI Cancers, Leads Investigator Sponsored Study at Memorial Sloan Kettering Cancer CenterTrial is Supported by…
Naporafenib is a potential first-in-class and best-in-class pan-RAF inhibitor in multiple RAS/MAPK pathway-driven tumors Initial SEACRAFT-1 Phase 1b combination data…